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MEK1 and AKT2 Mutations in Japanese Lung Cancer
Hidefumi Sasaki, MD, PhD, Yu Hikosaka, MD, Osamu Kawano, MD, Satoru Moriyama, MD, PhD,
Motoki Yano, MD, PhD, and Yoshitaka Fujii, MD, PhD
Background: Recently, to identify potential somatic mutations in
genes of epidermal growth factor receptor (EGFR) signaling path-
way, MEK1 gene mutation at exon 2 and mutation of the AKT2
(v-akt murine thymoma viral oncogene homologue 2) gene at kinase
domain have been reported in non-small cell lung cancer.
Methods: We investigated the MEK1 mutation (n 280) and AKT2
mutation (n  273) in surgically treated non-small cell lung cancer
cases. The presence or absence of MEK1 mutation (exon 2) and
AKT2 mutation at kinase domain was analyzed by direct sequences.
Results: MEK1 mutation (K57K) was found from 1 of 280 patients
with lung cancer (0.4%) and detected only one case (0.4%) of AKT2
mutation (R371H) in our cohort. MEK1 mutation was exclusive with
EGFR, K-ras, and B-raf mutations at kinase domain. However,
AKT2 mutation was coexisted with EGFR and PIK3CA mutations.
Conclusion: This study demonstrated that mutation in the kinase
domain of AKT2 and MEK1 exon 2 mutation occurred in a small
fraction of Japanese lung cancers.
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The mitogen-activated protein kinase (MAPK) pathwayplays a major role in the epidermal growth factor receptor
(EGFR) signaling cascade. After activation of EGFR signal-
ing, key downstream steps involve phosphorylation by RAF1
kinase of two distinct serine residues on both MEK1 and
MEK2, upstream of the ERK1/ERK2 MAPK module.1
MEK1 is the main activator of both ERK1 and ERK2 and the
critical isoform regulating tumor cell proliferation in vitro
and in vivo.2 More recently, MEK1 mutation at exon 2 was
identified by mutational analysis EGFR signaling pathway genes
in lung adenocarcinoma.3 Activation of the intracellular prosur-
vival signal transduction protein AKT(v-akt murine thymoma
viral oncogene) has been proposed as a central signaling event in
carcinogenesis,4 key downstream steps of EGFR, and has been
shown in experimental models to confer chemoresistance in
lung cancer.5 In addition, expression of the activated form of the
cell survival protein Akt (phospho Akt) in primary non-small
cell lung cancer is an independent indicator of poor prognosis.6
Previous report indicated that there were AKT2 mutations
(2.5%) at kinase domain in lung cancers; however, no AKT 1
and 3 mutations at kinase domain.7
Because we have previously found the other kinase
mutation, EGFR mutation was predominantly found in Jap-
anese population,8–11 we investigated MEK1 and AKT2 gene
status, mainly focused on adenocarcinomas by direct se-
quences. After retrospective pathologic review of lung can-
cers, some of the sampled defined as other pathologic sub-
types. The findings were compared with the clinicopathologic
features of lung cancer.
PATIENTS AND METHODS
Patients
The study group included patients with lung cancer
who had undergone surgery at the Department of Surgery,
Nagoya City University Hospital. The study was approved by
ethics committee of Nagoya City University Graduate School
of Medical Sciences. The lung tumors were classified accord-
ing to the general rule for clinical and pathologic record of
lung cancer in Japan.12 The clinical and pathologic charac-
teristics of the 280 patients with lung cancer for MEK1 gene
analyses were as follows: 164 (58.6%) were men, and 116
were women. Four were diagnosed as squamous cell carci-
nomas, 273 were adenocarcinomas, and three were adeno-
squamous cell were carcinoma. One hundred fifty-three (54.6%)
were smokers, and 127 were nonsmokers. The clinical and
pathologic characteristics of the 273 patients with lung cancer
for AKT2 gene analyses were as follows: 149 (54.6%) were
men and 124 were women. Fifteen were diagnosed as squa-
mous cell carcinomas, 250 were adenocarcinomas, and eight
were adenosquamous cell were carcinoma. One hundred
thirty-five (49.5%) were smokers, and 138 were nonsmokers
(Table 1).
Polymerase Chain Reaction Assays for MEK1
and AKT2
All tumor samples were immediately frozen and stored
at 80°C until assayed. Total RNA was extracted from lung
cancer tissues using Isogen kit (Nippon gene, Tokyo, Japan)
according to the manufacturer’s instructions. RNA concen-
tration was determined by spectrophotometer and adjusted to
a concentration of 200 ng/ml. About 10 cases were excluded
for each assay because tumor cells were too few to suffi-
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ciently extract tumor RNA. RNA (1 g) was reverse tran-
scribed by Superscript II enzyme (Gibco BRL, Gaithersburg,
MD) with 0.5 g oligo (dT)12–16 (Amersham Pharmacia
Biotech Inc. Piscataway, NJ). The reaction mixture was
incubated at 42°C for 50 minutes and then at 72°C for 15
minutes. We then used 1 L of each DNA for polymerase
chain reaction (PCR) analyses. The PCR reactions were
performed using LA-Taq kit (Takara Bio Inc, Shiga, Japan) in
a 25-L reaction volume. The primer sequences for MEK1
gene for exon 2 were as follows: the forward primer,
5-CCGACGGCTCTGCAGTTA-3, and the reverse primer,
5-TGTTCAGGAATTCTTCCAGCTT-3 (448bp). The cy-
cling conditions were as follows: initial denaturation at 94°C
for 5 minutes, followed by 40 cycles at 94°C for 45 seconds,
60°C for 45 seconds, and 72°C for 45 seconds. The primer
sequences for AKT2 gene for kinase domain were as follows:
the forward primer, 5-GACAAAGATGGCCACATCAA-3,
and the reverse primer, 5-CTGGGCGGTAAATTCATCAT-3
(489bp, exons 9–12). The cycling conditions were as follows:
initial denaturation at 94°C for 5 minutes, followed by 40
cycles at 94°C for 45 seconds, 58°C for 45 seconds, and 72°C
for 45 seconds. The products were purified by Qiagen PCR
purification kit (Qiagen, Valencia, CA). These samples were
sequenced by ABI prism 3100 analyzer (Applied Biosystems
Japan Ltd., Tokyo, Japan) and analyzed by BLAST and
chromatograms by manual review. The results of EGFR
mutation statuses at kinase domain were already reported.8–11
Statistical Analyses
Statistical analyses were done using the Mann-Whitney
U test for unpaired samples and Wilcoxon singed rank test for
paired samples. Linear relationships between variables were
determined by means of simple linear regression. Correlation
coefficients were determined by rank correlation using Spear-
man test and 2 test. The overall survival of patients with lung
cancer was examined by the Kaplan-Meier methods, and
differences were examined by the log-rank test. All analysis
was done using the Stat-View software package (Abacus
Concepts Inc. Berkeley, CA) and was considered significant
when the p value was less than 0.05.
RESULTS
Using the primers sets for MEK1 exon 2, when we
visualized the PCR products with 1% agarose gel, these
samples were further studied. In our cohort, 1 of 280 patients
had MEK1 mutation, K57N (Figure 1). The patient was male
and smoker. The MEK1 mutation was exclusive with B-raf,
K-ras, and EGFR mutation at kinase domain.
Retrospective pathologic review demonstrated that the
MEK1 mutant sample was adenocarcinoma (poorly differen-
tiated) with mixed subtype, 60% of solid and 40% of acinar
components. The patient was dead 5 months after surgery for
his recurrence of cancer. Because of the rapid growth, the
patients did not receive chemotherapy.
We have also sequenced for kinase domain of AKT2 gene
from 273 non-small cell lung cancer samples. Of 273 patients,
from direct sequencing using cDNA samples, we found only one
mutation at exon 11 (G1112A, R371H) (Figure 2). Adjacent
normal lung tissue sample showed wild-type sequence that
suggested that the mutation was somatic. This patient was
female, nonsmoker with well differentiated adenocarcinoma.
Pathologic stage was T1N2 (stage IIIa). The patient also had the
L861Q type mutation in EGFR exon 21 and PIK3CA mutation
(E542Q). The patients received EGFR TKI-based therapy for
her recurrence, however, less effective than would be expected
in the broader population of patients with an activating EGFR
mutation. The patient was dead 33 months after surgery for her
recurrence of cancer.
FIGURE 1. MEK1 gene mutation. One hundred seventy-one
nucleotide change from G to T at exon 2, introduces a sub-
stitution of lysine (K) to asparagine (N) at amino acid posi-
tion 57 (K57N) of the MEK1 protein.
TABLE 1. Clinicopathologic Data of Patients with Lung
Cancer
Factors
Status
MEK1 Study AKT2 Study
Mean age (yr) 65.6  9.1 64.6  9.1
Stage
I 175 (62.5%) 170 (62.3%)
II–IV 105 (37.5%) 103 (37.7%)
Lymph node metastasis
N0 203 (72.5%) 192 (70.3%)
N 77 (27.5%) 81 (29.7%)
Smoking
Never smoker 127 (45.3%) 135 (49.5%)
Smoker 153 (54.6%) 138 (50.5%)
EGFR mutation
Wild type 160 (57.1%) 162 (55.7%)
Mutation 120 (42.9%) 121 (44.3%)
Pathologic subtypes
Adeno 273 (97.5%) 250 (91.6%)
Nonadeno 7 (2.5%) 23 (8.4%)
Age
65 138 (49.3%) 131 (48.0%)
65 142 (50.7%) 142 (52.0%)
Gender
Male 164 (58.6%) 149 (54.6%)
Female 116 (41.4%) 124 (45.4%)
N, lymph node metastasis positive; adeno, adenocarcinoma.
Sasaki et al. Journal of Thoracic Oncology • Volume 5, Number 5, May 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer598
DISCUSSION
We obtained findings that MEK1 K57N mutation status
was rare in Japanese cohort (0.4%) and exclusive with B-raf,
K-ras, and EGFR mutation of adenocarcinoma patients. We
have also found somatic AKT2 mutation at kinase domain in
0.4% of Japanese lung cancers. Although the incidence of
AKT2 mutations was low, the location of the mutation at an
important functional site (the kinase domain) suggested that
AKT2 mutation might possibly contribute to the pathogenesis
of lung cancer. Because we used direct sequencing for
screening purpose, the frequency of these mutations might be
underestimated, probably not enough for detection of all
mutated cases.
The previous report showed the somatic mutation in
MEK1 in human lung tumors, but not in colon, breast,
prostate, and pancreas carcinomas, identified by mutational
profiling of genes encoding EGFR signaling pathway proteins
in a large cohort of lung adenocarcinomas.1,13
In the previous report, the same heterozygous mutation,
K57N, was found in two of 207 lung adenocarcinomas,
neither of which harbored mutations in other genes encoding
components of the EGFR signaling pathway, such as EGFR,
K-ras, B-raf, and PIK3CA.3 Functional characterization of
mutant in vitro indicated that its expression in 293T cells lead
to constitutive activation of downstream signaling compo-
nents.14 Thus, MEK1 K57N mutant display gain-of-function
properties.14 K57 is highly conserved among various species3
and located in a region between the nuclear export signal
(amino acids 33–44) and catalytic domain (amino acids
68–271) of MEK1. Consistent with the G to T mutation, a
type of transversion known to be smoking related, the sample
was from smokers. The K57N substitution leads to constitu-
tive activation of the MAPK pathway in vitro (Ba/F3 cell).3
Akt has been found to play a role in the survival of
cancer cells.15–18 The importance of AKT in human cancer is
largely inferred from common recurring mutations in en-
zymes that produce or degrade short-lived second messenger
phospholipids and consequently indirectly activate AKT
through membrane recruitment.
Among the members of the AKT family, AKT2 is
associated with the development of human cancers. Overex-
pression of the AKT2 is observed in 20% of pancreatic
adenocarcinoma.19 Transfection of antisense AKT2 RNA into
pancreatic adenocarcinoma cell lines inhibits its tumorigen-
esity.20 AKT2 expression correlated with prognosis of human
hepatocellular carcinoma.21 Previous report investigated that
one of 79 lung cancer case had missense AKT2 mutation.
Proteins along the AKT signaling pathway, including
K-ras, EGFR, erbB2, and Braf, are frequently mutated in lung
cancers8,21–23 and act as oncogenic proteins. Of these genes,
we found a coincidence of an AKT2 mutation in a lung
adenocarcinoma, suggesting that alterations in the AKT sig-
naling by both AKT2 and EGFR mutation can occur and
could possibly contribute together to the pathogenesis of lung
adenocarcinomas.
In summary, MEK1 and AKT2 mutations in Japanese lung
cancers seemed to be extremely rare; however, these mutations
might be a role in function. Because we used surgical resected
samples, we would like to test for these mutations in a cohort of
patients with more advanced lung cancer.
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